Neurocrine Biosciences names Eiry W. Roberts chief medical officer, replacing Sanjay Keswani

By Public Technologies
  • Neurocrine Biosciences named Eiry W. Roberts as chief medical officer, effective immediately.
  • Sanjay Keswani will leave the company under a mutual agreement.
  • Roberts previously served as chief medical officer from 2018 to 2025, most recently acting as a strategic advisor.
  • She spent 26 years at Eli Lilly, including as vice president of research and development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609281605PR_NEWS_USPR_____LA58413) on September 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk